Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NIH Research Grant:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Stock:
"read the dutton report"
An old outdated report. Many things have "changed" with the co...new projects on the horizon...Stocky, you have the opportunity of reading the positive updates here, and I think you have. You just seem to want to give a negative slant to positive news.
Take care,
Ann
Stockholder:
"I believe once Biofrontera goes public, DNAG would likely release more specifically with them."
A good time to bring up this issue up at the June stockholder's meeting...agreed? But, until then...after six years in this investment, there have been many potential dreams and successes we hoped would materialize sooner, but are still left with a few connecting dots.
I will definitely share in your enthusiasm "when/if" BIO going public materializes...and I sincerely hope it does!!
Cheers,
Ann
A new era for DNAP?
SARASOTA, FL -- (MARKET WIRE) -- 10/12/2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has established DNAPrint Pharmaceuticals, Inc., a new wholly owned pharmaceutical subsidiary focused on personalized medicine.
Take care,
Ann
Richard Gabriel's Radio address:
http://www.marketwire.com/mw/release_html_pressroom?id=F65B254181F3F030&release_id=132263
Ann
This happened when we got our Ad Agency:
http://www.bioportfolio.com/july_05/26_07_2005/DNAPrint_genomics_Launches.html
Ann
Michiko:
Since, I will not be bringing that topic up at the meeting - good luck to you and be sure to report back to us! - lol
My best,
Ann
Michi:
OT:
"Do you know the meaning of "Pipi" in Germany?"
Not in German - lol
(let me know, Michi)
Take care,
Ann
You got it, Stock!
Take care,
Ann
A look[back at Biofrontera & DNAP merger:
``We believe our investment in Biofrontera will prove to be beneficial to DNAPrint genomics and to our shareholders,'' said DNAPrint genomics President and Chief Executive Officer Richard Gabriel. ``It validates our decision to build a collaborative relationship with Biofrontera in advance of its anticipated initial public offering.''
``Biofrontera is an excellent business partner for us because of its drug-product pipeline,'' said Hector J. Gomez, Ph.D., Chairman and Chief Medical Officer at DNAPrint genomics. ``We are pleased with our relationship with Biofrontera, and we have the highest confidence in its management team. We are confident the new funding will assist Biofrontera in advancing its drugs into the market.''
Mr. Gabriel and Dr. Gomez both are members of Biofrontera's Board of Directors.
``DNAPrint genomics, Inc. and its support were crucial to our securing this new financing,'' said Prof. Hermann Lubbert, Chief Executive Officer of Biofrontera AG. ``We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs,'' he concluded.
Ann
Scotland Yard & DNAP:
http://moneyextra.uk-wire.com/cgi-bin/articles/20040428210700NZ277.html
Ann
whoa!
My apologies for errors - it's all the keyboard's fault!
Ann
DBAP...DBAP...DNAP...
If you read on - it's all part of DNAP's Pipiline:
"Revenues in the first quarter of 2006 increased 181% to $678,000, compared with $241,000 in the corresponding period a year ago. Most of the increase was attributable to the Company's ANCESTRYbyDNA products and the Company's genotyping services. "Our newly acquired Canadian subsidiary, Ellipsis Biotherapeutics, contributed $227,000 in genotyping revenues," Mr. Gabriel said. "Also, ANCESTRYbyDNA received coverage in many national media outlets, which increased interest in our technology. Although growth in the current second quarter is not continuing at the same high first-quarter rate for our genotyping services, we anticipate that ANCESTRYbyDNA will continue to be a popular product for the remainder of 2006 and beyond."
Ann
DBAP Business Update 5/06:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=3732482
Ann
Race & DNAP is real:
"To project this to DNAPrint – what would be needed for accurate analysis of actual direct ancestry are more AIMs, more powerful algorithms, and – very important – more and more varied parental populations to determine the allele frequencies. And the authors of the Yang study seem to understand that the same limitations apply to their work. However, the data in both cases are perfectly sound in getting a solid view of the relative, comparative genetic (“ancestral”) components of different groups, and thus to “bin” individuals into different clusters of major groups, as well as the identification of admixture within groups and individuals.
In both cases – Yang and DNAPrint – “blind” studies of individuals correctly identify majority race with ~ 100% accuracy, as well as identify, in many cases, significant admixture consistent with known population histories and with individual phenotypes. The point being, in the last analysis, is that while a more perfect analysis would be able to detect “true ancestry” and complete “population diversity” (including Australian aboriginals, Papuans, etc.), the more limited set of AIMs and parental populations are currently sufficient to identify major racial and sub-racial populations, and admixture of these, by observing the patterns of genetic components characteristic of each group.
Thus, even if DNAPrint (or Yang et al) would label the different clusters as A,B,C, D and NOT with actual names of population groups, and even if we did not know the exact origin of these genetic components, we could say, for example, that North Europeans are characterized by, typically, a profile of proportions 6A, 2B, 1C, and 1D, while Southern Europeans were 3A, 4B, 2C, and 1D, and Middle Easterners were 0A, 1B, 6C, and 2D, etc.
In any case, in summary:-
Race is real. And South Asians are a different race than Europeans. And the results of the Yang paper are generally consistent with the broad outlines of the racial and sub-racial DNAPrint data.
Ann
http://majorityrights.com/index.php/weblog/comments/the_yang_paper_and_the_reality_of_race/
DNAP mentioned in reality of race.
Ann
Meeting of Stockholders:
http://www.sec.gov/Archives/edgar/data/1127354/000123174206000376/dnagdef14c.txt
Ann
Worktoplay - you're the best! Lots of confidence in you, always!
Take care,
Ann
Since this is subject of discussion, the following is posted by Grateful - thank you, sir:
"I don’t want to spoil the story for anyone who is planning to read it, but here’s an excerpt… (the Dr. Reid character, I’m certain, is based on Tony Frudakis…)"
…“A genealogical history,” Dr. Reid explains over the phone. Based on four major biogeographical ancestry groups, sub-Saharan African, Indo-European. East Asia, or Native American, or an admixture.
Technology based on SNPs” Dr. Reid is explaining. “Single Nucleotide Polymorphisms. Different from normal DNA screening that requires the analysis of millions of base pairs of genes when looking for patters, may of them irrelevant. Basically, what we’re interested in are the some two thousand ancestry information markers….”
Win listens to a typical scientist typically over explaining, going on and on about some beta version of some machine that is 99.99 percent accurate, about some test that can predict human eye color from DNA with 95 percent accuracy, about Harvard Medical School and a license the lab has with it to develop some anemia drug…
“Whoa.” Win stops rocking, “What do drugs have to do with this?”
“Pharmacogenetics. When we started doing ancestral profiling, it wasn’t to work with criminal cases. The original objective was to assist pharmaceutical companies with determining how genetics can be applied to developing drugs.”
“You’ve got something going on with Harvard Medical School?” Win gets a feeling, a strong one.
“Maybe you’ve heard of PROHEMOGEN [ERYTHROPOIETIN]? For the treatment of anemia associated with renal failure, cancer chemotherapy, Zidovudine-treated HIV. Can help reduce the need for blood transfusion.”
It goes on from here, but you get the idea. Here’s another excerpt…
“buying shares in the high-tech DNA lab that’s about to get a lot of attention…”
“PROHEMOGEN,” Win then says, “DNA technology that genetically matches patients with drugs. The lab you picked for you media extravaganza may do ancestral profiles in criminal cases, but that’s not where the money is.”
“The money’s in using genomics to help with the development of these next-generation superdrugs. Huge money, huge,” Win says.
If you want to see where the story goes from here, you’ll have to read the book…
Ann
Jeves:
"AT RISK, by Patricia Cornwell. (Putnam, $21.95.) A Massachusetts state investigator applies DNA and other forensic techniques to a cold murder case; written as a serial for The New York Times Magazine."
Ann
Stock:
"it's in German, I cannot read it!"
Michiko? Your assistance? You think, Stock? Since she resides in Germany?
Ann
Jever:
OT
"I think zooluu has lost his mind!!!!"
What mind? - lol
Take care,
Ann
"abgke on DNAP" - lol
Might as well be a basher...my best at late hrs.
Sorry, All
Ann
Whoa...sorry
Trace DNA-based Acestry tests:
http://www.tracegenetics.com/newsevents.html
Ann
Trace Genetics Services & Functions:
http://www.tracegenetics.com/services_custom.html
Ann
A Naked Short List abgke on DNAP - interesting:
http://www.stockhouse.com/news/news.asp?tick=SVNX&newsid=3733349
Ann
For all:
Listen to Richard re: Radio Network on DNAP:
http://www.marketwire.com/mw/frame_multimedia?prid=132263&attachid=274885
Ann
Annual Meeting of Stockholders & Proxy Vote:
http://www.sec.gov/Archives/edgar/data/1127354/000123174206000376/dnagdef14c.txt
Ann
An interesting article out today on DNA/bacteria & drug reactions:
Gene Experts: 'We Are Not Entirely Human'
By Maggie Fox
Reuters
WASHINGTON (June 1) - We may not be entirely human, gene experts said on Thursday after studying the DNA of hundreds of different kinds of bacteria in the human gut.
Bacteria are so important to key functions such as digestion and the immune system that we may be truly symbiotic organisms -- relying on one another for life itself, the scientists write in Friday's issue of the journal Science.
Their findings suggest that studying bacteria native to our bodies may provide important clues to disease, nutrition, obesity and how well drugs will work in individuals, said the team at The Institute for Genomic Research, commonly known as TIGR, in Maryland.
"We are somehow like an amalgam, a mix of bacteria and human cells. There are some estimates that say 90 percent of the cells on our body are actually bacteria," Steven Gill, a molecular biologist formerly at TIGR and now at the State University of New York in Buffalo, said in a telephone interview.
"We're entirely dependent on this microbial population for our well-being. A shift within this population, often leading to the absence or presence of beneficial microbes, can trigger defects in metabolism and development of d They also synthesize vitamins that people cannot.
"Humans have evolved for million of years with these bacteria. And they provide essential functions," Gill said.
GERM SURPRISE
Gill and his team sequenced the DNA in feces donated by three adults. They found a surprising amount of it came from bacteria.
They compared the gene sequences to those from known bacteria and to the human genome and found this so-called colon microbiome -- the entire sum of genetic material from microbes in the lower gut -- includes more than 60,000 genes.
That is twice as many as found in the human genome.
"Of all the DNA sequences in that material, only 1 to 5 percent of it was not bacterial," Gill said.
"We were surprised."
They also found a surprising number of Archaea, also known as archaebacteria, which are genetically distinct from bacteria but which are also one-celled organisms often found in extreme environments such as hot springs.
The donors were healthy adults. None had taken antibiotics for a year, as these drugs are known to disturb the bacteria in the body.
Gill said his team hopes now to make a comparison of the gut bacteria from different people.
"The ideal study would be to compare 20 people, 30 people from different ethnic backgrounds, different diets, drinkers, smokers, and so on, because I think there are going to be distinct differences," Gill said.
These bacteria almost certainly help break down drugs that people take and studying the effects of different populations of the microbes might provide clues to treating different people with various medications.
The next study will focus on the bacteria in the mouth, Gill said. There are at least 800 species in the mouth and maybe more, Gill said.
Ann
Hand:
http://www.ibia.org/biometrics/technologies_view.asp?id=7
More later,
Ann
3-D - Dermis/Skin:
http://www.ibia.org/biometrics/technologies_view.asp?id=10
Ann
3-D Biometrics:
http://www.ibia.org/biometrics/industrynews_view.asp?id=69
Ann
Edgar On-Line on DNAP:
http://yahoo.brand.edgar-online.com/default.aspx?cik=1127354
Ann
Fru & Zoo:
OT:
"I hope this will ignite a meaningful discussion"
Fru, was hoping you were taking your little brother, Luu, to the Zoo today!
That's as meaningful as it gets - lol
Ann
Stock:
We, of course, will be watching it.
Take care,
Ann